home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Software Vault: The Sapphire Collection
/
Software Vault (Sapphire Collection) (Digital Impact).ISO
/
cdr16
/
med9410d.zip
/
M94A0711.TXT
< prev
next >
Wrap
Text File
|
1994-10-21
|
3KB
|
49 lines
Document 0711
DOCN M94A0711
TI Molecular targets for HIV therapy.
DT 9412
AU Rosenberg M; SmithKline Beecham Pharmaceutical, King of Prussia,
Pennsylvania; 19406-0939.
SO Annu Conf Australas Soc HIV Med. 1993 Oct 28-30;5:25 (abstract no.
SPI-3). Unique Identifier : AIDSLINE ASHM5/94348944
AB There continues to be an urgent need for the discovery and design of
better drugs with antiviral activities against the HIV viruses. The
various stages of the HIV life cycle provide specific molecular targets
for which novel assays and mechanistic approaches can be developed to
search for and identify new inhibitory agents. For example, viral
replication, integration, gene expression, and maturation are dependent
on the presence and function of specific virally encoded gene products
such as the reverse transcriptase, required for RNA-dependent DNA
synthesis prior to integration of the pro-viral DNA into the host
genome; integrase, the enzyme responsible for the integration event; the
TAT and REV regulatory proteins involved in transactivating viral gene
expression within the host; and protease, the enzyme responsible for
proteolytic maturation of the viral precursor polyproteins. In addition,
viral recognition and entry into human cells also provides certain
molecular targets for potential intervention. For example, the
interaction of the viral envelope with the CD4 receptor found on human
lymphocytes and other cells is utilized by free virus as a route of cell
entry and also is involved in the direct cell-to-cell spread of the
virus. A variety of recombinant molecular technologies have been used to
isolate and characterise the various proteins which function as these
key molecular targets of viral growth and development. Specific assays
have been developed utilizing these proteins in order to 1) Screen
synthetic and natural products and identify potential anti-viral
compounds, and 2) Test drugs designed to be inhibitory based on either
a) the characterisation and elucidation of mechanism of action of the
target or b) on the structure of compounds discovered by screen. The
results obtained to date and the future perspectives for using these
molecular targeted approaches will be described and discussed.
DE Antiviral Agents/*THERAPEUTIC USE DNA
Nucleotidyltransferases/ANTAGONISTS & INHIB Gene Expression Regulation,
Viral/DRUG EFFECTS/GENETICS Gene Products, rev/ANTAGONISTS &
INHIB/GENETICS Gene Products, tat/ANTAGONISTS & INHIB/GENETICS Human
HIV/*DRUG EFFECTS/GENETICS HIV Infections/*DRUG THERAPY/MICROBIOLOGY
HIV Protease Inhibitors/THERAPEUTIC USE Reverse
Transcriptase/ANTAGONISTS & INHIB Virus Replication/DRUG
EFFECTS/GENETICS MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).